cosaar 100 mg filmtabletten
merck sharp & dohme gesellschaft mbh - losartan kalium - losartan
carboplatin onkovis 10 mg/ml infusionslösung
onkovis gmbh (8111905) - carboplatin - infusionslösung - teil 1 - infusionslösung; carboplatin (23168) 50 milligramm
bicalutamid kabi 50 mg filmtabletten
fresenius kabi austria gmbh - bicalutamid -
tagrisso
astrazeneca ab - osimertinib mesilate - karzinom, nicht kleinzellige lunge - andere antineoplastische wirkstoffe, die protein-kinase-inhibitoren - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
triplixam 10 mg - 2.5 mg - 10 mg (impexeco) film-coat. tabl.
triplixam 10 mg - 2.5 mg - 10 mg (impexeco) compr. pellic.
triplixam 10 mg - 2.5 mg - 10 mg (impexeco) filmomh. tabl.
triplixam 10 mg - 2.5 mg - 5 mg (impexeco) film-coat. tabl.
triplixam 10 mg - 2.5 mg - 5 mg (impexeco) compr. pellic.
triplixam 10 mg - 2.5 mg - 5 mg (impexeco) filmomh. tabl.